-
Product Insights
NewNet Present Value Model: Moleculin Biotech Inc’s Annamycin
Empower your strategies with our Net Present Value Model: Moleculin Biotech Inc's Annamycin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STAR-0602 in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Oropharyngeal Cancer Drug Details: STAR-0602 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Soft Tissue Sarcoma Drug Details: L-Annamycin is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Relapsed Acute Myeloid Leukemia Drug Details: L-Annamycin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Refractory Acute Myeloid Leukemia Drug Details: L-Annamycin...
-
Product Insights
Recurrent Malignant Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Malignant Glioma - Drugs In Development, 2023’, provides an overview of the Recurrent Malignant Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...
-
Product Insights
Pleomorphic Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleomorphic Liposarcoma - Drugs In Development, 2023’, provides an overview of the Pleomorphic Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleomorphic Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ependymoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ependymoma - Drugs In Development, 2023’, provides an overview of the Ependymoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Angiosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Angiosarcoma - Drugs In Development, 2023’, provides an overview of the Angiosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2023’, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...